RenovoRx Inc., a biopharmaceutical company focused on localized treatment of solid tumors, is proud to announce the addition of Leesa Gentry to the Company’s executive management team as Senior Vice President of Clinical Operations.
Ms. Gentry brings with her invaluable experience and expertise in clinical trials management, and joins the team alongside COO Angela Gill Nelms, CFO James Ahlers, and Vice President and Controller Ron Kocak. With her addition, RenovoRx is well-positioned to further advance studies in cancer treatment.
Ms. Gentry is a powerhouse in the clinical research industry, bringing nearly three decades of experience to the table. After serving in pivotal roles at IQVIA (Quintiles), PPD, OmnicareCR, and Otsuka, she was most recently the Senior Vice President of Clinical Operations at Evotec (NASDAQ: EVO).
While at PPD, she led the development of one of the pharmaceutical industry’s first clinical trial management systems, illustrating her knack for pushing the boundaries of innovation.
Ms. Gentry has made a tremendous impact in the clinical research field, being featured in the Good Clinical Practice Journal for her work in growing the clinical research site network within long-term care and the Bulletin of the World Health Organization for her innovative strategies for streamlined trial implementation in clinical operations, data management and third-party collaboration.
At Otsuka, her creative approaches for registration trial implementation in resource-constrained environments have been highly regarded.
RenovoRx is thrilled to welcome Leesa as its new clinical operations leader. With decades of industry experience, she is sure to make an immediate impact in optimizing the company’s clinical trials.
With positive interim analysis data from their Phase III pancreatic cancer treatment, RenovoRx is now more confident than ever in their mission to extend patient lifespans and improve quality of life through innovative oncology therapies.
Thanks to Leesa’s successful record with regulatory submissions, late-stage trial preparation, and clinical execution, RenovoRx is confident that she will be an invaluable asset in their pursuit for these life-saving treatments.
Ms. Gentry is thrilled to be part of the RenovoRx team, and she believes that the company is changing the current standard of care for Locally Advanced Pancreatic Cancer (LAPC). With interim data showing promising results in overall survival and quality of life, the progress made by RenovoRx is remarkable.
Ms. Gentry is confident that the company’s pipeline and anticipated clinical milestones will help patients with difficult-to-treat cancers, and she is looking forward to the potential that RenovoRx holds.
About RenovoRx, Inc.
RenovoRx is on a mission to revolutionize the way cancer is treated. Our proprietary RenovoTAMP® therapy platform aims to deliver chemotherapy directly to solid tumors, avoiding the harsh side effects typical of systemic delivery methods, so that patients can enjoy more time with their loved ones.
RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and its patented delivery system, RenovoCath®, that is currently being studied in the Phase III TIGeR-PaC clinical trial for the treatment of locally advanced pancreatic cancer. With RenovoGemTM, we are striving to improve safety, tolerance, and widen the therapeutic window for oncology treatment.
RenovoRx is revolutionizing cancer treatment with its therapy platform and product candidates that have been granted an impressive patent portfolio, including eight issued U.S. patents, one issued European patent, and several additional patents pending in the US, EU and Asia.
On top of that, the company has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine to treat pancreatic cancer and bile duct cancer (cholangiocarcinoma). This is a major breakthrough in the fight against cancer and shows RenovoRx’s commitment to improving the lives of cancer patients.